Syensqo announced its successful listing on Euronext Brussels and Euronext Paris under ticker SYENS on December 11, after Syensqo was demerged from Solvay on December 8.

Syensqo was successfully listed on Euronext.

The listing marks a historical milestone as the company embarks on an exciting, innovation-driven journey focused on delivering superior growth and value creation.

Syensqo owns a unique portfolio of market leading solutions addresses environmental and social challenges, through electrification, lightweight, connectivity, resource efficiency, and serving a healthier quality of life for all.

With 41% of FY2022 net sales in net sales in the Americas, 36% in Asia-Pacific and 23% Europe, Syensqo’s long term ambition is to grow on average at around two times the rate of its main end markets, while further improving its best-in-class margin and returns.

Upon listing, Syensqo has 105,876,417 ordinary shares in issue, each carrying one voting right. Its share price started at a value of EUR 90 at market open, which corresponds to a market capitalization of EUR 9.53 billion.

“We are thrilled to begin our journey on Euronext. With SYENS in both our name and ticker, we are now officially launched as a science company, one of the largest publicly traded specialty companies in the world,” said Dr. Ilham Kadri, CEO of Syensqo.

Syensqo is expected to be included in major stock market indices such as BEL20, Stoxx Europe 600, MSCI Europe, FTSE Russell, among others, subject to the timing of each individual index review.

Syensqo announced its successful listing on Euronext Brussels and Euronext Paris under ticker SYENS on December 11, after Syensqo was demerged from Solvay on December 8.

Syensqo was successfully listed on Euronext.

The listing marks a historical milestone as the company embarks on an exciting, innovation-driven journey focused on delivering superior growth and value creation.

Syensqo owns a unique portfolio of market leading solutions addresses environmental and social challenges, through electrification, lightweight, connectivity, resource efficiency, and serving a healthier quality of life for all.

With 41% of FY2022 net sales in net sales in the Americas, 36% in Asia-Pacific and 23% Europe, Syensqo’s long term ambition is to grow on average at around two times the rate of its main end markets, while further improving its best-in-class margin and returns.

Upon listing, Syensqo has 105,876,417 ordinary shares in issue, each carrying one voting right. Its share price started at a value of EUR 90 at market open, which corresponds to a market capitalization of EUR 9.53 billion.

“We are thrilled to begin our journey on Euronext. With SYENS in both our name and ticker, we are now officially launched as a science company, one of the largest publicly traded specialty companies in the world,” said Dr. Ilham Kadri, CEO of Syensqo.

Syensqo is expected to be included in major stock market indices such as BEL20, Stoxx Europe 600, MSCI Europe, FTSE Russell, among others, subject to the timing of each individual index review.